메뉴 건너뛰기




Volumn 71, Issue 2, 2013, Pages 307-319

Sunitinib combined with pemetrexed and cisplatin: Results of a phase i dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma

Author keywords

Cisplatin; NSCLC; Pemetrexed; Phase I; Solid tumors; Sunitinib

Indexed keywords

CISPLATIN; PEMETREXED; SUNITINIB;

EID: 84874112681     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2008-6     Document Type: Article
Times cited : (17)

References (32)
  • 1
    • 78650874372 scopus 로고    scopus 로고
    • SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
    • 12748309 1:CAS:528:DC%2BD3sXkvVersbw%3D
    • Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478
    • (2003) Mol Cancer Ther , vol.2 , pp. 471-478
    • Abrams, T.J.1    Lee, L.B.2    Murray, L.J.3    Pryer, N.K.4    Cherrington, J.M.5
  • 2
    • 33947504730 scopus 로고    scopus 로고
    • Sunitinib: From rational design to clinical efficacy
    • 17327610 10.1200/JCO.2006.06.3602 1:CAS:528:DC%2BD2sXjvVKmtLY%3D
    • Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896
    • (2007) J Clin Oncol , vol.25 , pp. 884-896
    • Chow, L.Q.1    Eckhardt, S.G.2
  • 8
    • 36249021985 scopus 로고    scopus 로고
    • Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling
    • 17691110 10.1002/ijc.22999 1:CAS:528:DC%2BD2sXhtl2qsLzF
    • Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C (2007) Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 121:2606-2614
    • (2007) Int J Cancer , vol.121 , pp. 2606-2614
    • Hasumi, Y.1    Klosowska-Wardega, A.2    Furuhashi, M.3    Ostman, A.4    Heldin, C.H.5    Hellberg, C.6
  • 9
    • 0031045574 scopus 로고    scopus 로고
    • Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer
    • 9052396 10.1038/bjc.1997.83 1:CAS:528:DyaK2sXhslWisLc%3D
    • Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Comley M, Whitehouse RM, Talbot DC, Gatter KC, Harris AL (1997) Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 75:477-481
    • (1997) Br J Cancer , vol.75 , pp. 477-481
    • Koukourakis, M.I.1    Giatromanolaki, A.2    O'Byrne, K.J.3    Comley, M.4    Whitehouse, R.M.5    Talbot, D.C.6    Gatter, K.C.7    Harris, A.L.8
  • 10
    • 23844545810 scopus 로고    scopus 로고
    • Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas
    • 16103075 10.1158/0008-5472.CAN-04-4171 1:CAS:528:DC%2BD2MXns1Wrur0%3D
    • Shikada Y, Yonemitsu Y, Koga T, Onimaru M, Nakano T, Okano S, Sata S, Nakagawa K, Yoshino I, Maehara Y, Sueishi K (2005) Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 65:7241-7248
    • (2005) Cancer Res , vol.65 , pp. 7241-7248
    • Shikada, Y.1    Yonemitsu, Y.2    Koga, T.3    Onimaru, M.4    Nakano, T.5    Okano, S.6    Sata, S.7    Nakagawa, K.8    Yoshino, I.9    Maehara, Y.10    Sueishi, K.11
  • 11
    • 0035863288 scopus 로고    scopus 로고
    • Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer
    • 11208836 1:CAS:528:DC%2BD3MXhtVekt7Y%3D
    • Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, Yang PC, Lee YC (2001) Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19:432-441
    • (2001) J Clin Oncol , vol.19 , pp. 432-441
    • Yuan, A.1    Yu, C.J.2    Kuo, S.H.3    Chen, W.J.4    Lin, F.Y.5    Luh, K.T.6    Yang, P.C.7    Lee, Y.C.8
  • 15
    • 72549097409 scopus 로고    scopus 로고
    • A phase i study evaluating administration of oral SU11248 (sunitinib malate) using a loading and maintenance dose on a 2/1 schedule in patients (pts) with advanced solid tumors
    • abstract 2911
    • Rosen LS, Bello CL, Mulay M, Dinolfo M, Baum C (2006) A phase I study evaluating administration of oral SU11248 (sunitinib malate) using a loading and maintenance dose on a 2/1 schedule in patients (pts) with advanced solid tumors. In: Proceedings of the 97th American Association for Cancer Research 47; abstract 2911
    • (2006) Proceedings of the 97th American Association for Cancer Research 47
    • Rosen, L.S.1    Bello, C.L.2    Mulay, M.3    Dinolfo, M.4    Baum, C.5
  • 20
    • 79955728914 scopus 로고    scopus 로고
    • Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial
    • abstract LBA308
    • Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Martell B, Hariharan S, Figlin RA (2011) Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT Trial. J Clin Oncol 29(Suppl 7); abstract LBA308
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. 7
    • Motzer, R.J.1    Hutson, T.E.2    Olsen, M.R.3    Hudes, G.R.4    Burke, J.M.5    Edenfield, W.J.6    Wilding, G.7    Martell, B.8    Hariharan, S.9    Figlin, R.A.10
  • 25
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
    • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3    Wanders, J.4    Kaplan, R.S.5    Rubinstein, L.6    Verweij, J.7    Van Glabbeke, M.8    Van Oosterom, A.T.9    Christian, M.C.10    Gwyther, S.G.11
  • 26
    • 1342267614 scopus 로고    scopus 로고
    • Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
    • 14760119 10.1093/annonc/mdh059 1:STN:280:DC%2BD2c%2FlvVamtg%3D%3D
    • Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257-260
    • (2004) Ann Oncol , vol.15 , pp. 257-260
    • Byrne, M.J.1    Nowak, A.K.2
  • 27
    • 77951230703 scopus 로고    scopus 로고
    • Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
    • 20423465 10.1186/1756-9966-29-38
    • Zhang GZ, Jiao SC, Meng ZT (2010) Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. J Exp Clin Cancer Res 29:38
    • (2010) J Exp Clin Cancer Res , vol.29 , pp. 38
    • Zhang, G.Z.1    Jiao, S.C.2    Meng, Z.T.3
  • 28
    • 42949148257 scopus 로고    scopus 로고
    • Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    • 18347007 10.1200/JCO.2007.14.5375 1:CAS:528:DC%2BD1cXmsFemsb8%3D
    • Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816
    • (2008) J Clin Oncol , vol.26 , pp. 1810-1816
    • Burstein, H.J.1    Elias, A.D.2    Rugo, H.S.3    Cobleigh, M.A.4    Wolff, A.C.5    Eisenberg, P.D.6    Lehman, M.7    Adams, B.J.8    Bello, C.L.9    Deprimo, S.E.10    Baum, C.M.11    Miller, K.D.12
  • 29
    • 79955728914 scopus 로고    scopus 로고
    • Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial
    • abstract LBA308
    • Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Martell B, Hariharan S, Figlin RA (2011) Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT Trial. J Clin Oncol 29(suppl 7); abstract LBA308
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. 7
    • Motzer, R.J.1    Hutson, T.E.2    Olsen, M.R.3    Hudes, G.R.4    Burke, J.M.5    Edenfield, W.J.6    Wilding, G.7    Martell, B.8    Hariharan, S.9    Figlin, R.A.10
  • 32
    • 79953029071 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
    • 21336183 10.1097/JTO.0b013e31820cf053
    • Camidge DR, Kono SA, Lu X, Okuyama S, Barón AE, Oton AB, Davies AM, Varella-Garcia M, Franklin W, Doebele RC (2011) Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 6:774-780
    • (2011) J Thorac Oncol , vol.6 , pp. 774-780
    • Camidge, D.R.1    Kono, S.A.2    Lu, X.3    Okuyama, S.4    Barón, A.E.5    Oton, A.B.6    Davies, A.M.7    Varella-Garcia, M.8    Franklin, W.9    Doebele, R.C.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.